Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Starting soon · Phase 3

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.

Key facts

Study ID

NCT07472413

Run by

University of Miami

People needed

60

Starts

2026-09-01

Expected to finish

2028-07-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages ≥18 years
• Able to read and speak in English or Spanish
• Able to and willing to give informed consent
• Diagnosis of Multiple Sclerosis (MS)
• Patients starting or currently receiving ocrelizumab, ublituximab, rituximab

You may not qualify if…

• Adults unable or unwilling to consent
• Patients younger than 18 years of age
• Pregnant women
• Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine
• Moderate or severe renal impairment (creatinine clearance or 11-31 mL/min or worse)
• Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2/proton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions)

Where it is running

• UHealth Boca Raton — Boca Raton, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.